Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.25 is 163% above its 5-year average of -0.39, near the high end of its 5-year range (-1.04–0.25).
As of the fiscal period ended Tuesday, June 30, 2026. 245.99% above its 12-month average of -0.17.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.25.
DEBT TO EQUITY RATIO
0.25
DEBT TO EQUITY RATIO AVG TTM
-0.17
DEBT TO EQUITY RATIO AVG 3Y
-0.48
DEBT TO EQUITY RATIO AVG 5Y
-0.39
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+245.99%
CURRENT VS 3Y AVG
+150.57%
CURRENT VS 5Y AVG
+162.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 649 covered companies
CURRENT VS SECTOR MEDIAN
+104.36%
vs the sector median at left
Envoy Medical, Inc.
Market Cap
$51.34M
Debt to Equity Ratio
0.25
TTM Avg
-0.17
3Y Avg
-0.48
5Y Avg
-0.39
Market Cap
$51.39M
Debt to Equity Ratio
0.09
TTM Avg
7.52
3Y Avg
4.55
5Y Avg
3.64
Market Cap
$51.13M
Debt to Equity Ratio
0.00
TTM Avg
0.89
3Y Avg
0.55
5Y Avg
0.44
Market Cap
$50.58M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$52.28M
Debt to Equity Ratio
0.05
TTM Avg
0.11
3Y Avg
0.11
5Y Avg
0.11
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Envoy Medical, Inc. (COCH) | $51.34M | 0.25 | -0.17 | -0.48 | -0.39 |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.39M | 0.09 | 7.52 | 4.55 | 3.64 |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | 0.30 | 0.25 | 0.31 | 0.39 |
| Clene Inc. (CLNN)vs › | $51.50M | N/A | 6.12 | 6.71 | 4.67 |
| INmune Bio, Inc. (INMB)vs › | $50.78M | 0.07 | 0.03 | 0.14 | 0.13 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.13M | 0.00 | 0.89 | 0.55 | 0.44 |
| Microbot Medical Inc. (MBOT)vs › | $50.58M | 0.01 | 0.02 | 0.04 | 0.04 |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.28M | 0.05 | 0.11 | 0.11 | 0.11 |
| Celularity Inc. (CELU)vs › | $50.37M | N/A | 4.70 | 2.51 | 1.98 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | 0.00 | 0.12 | 0.06 | 0.04 |
Debt/Equity
0.25
Current Ratio
1.73
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.25 |
| 2026-03-31 | 0.08 |
| 2025-12-31 | -0.08 |
| 2025-09-30 | -0.13 |
| 2025-06-30 | -0.97 |
| 2025-03-31 | -0.99 |
| 2024-12-31 | -1.04 |
| 2024-09-30 | -0.84 |
| 2024-06-30 | -0.69 |
| 2024-03-31 | -0.72 |
| 2023-12-31 | -0.32 |
| 2023-09-30 | 0.09 |
| 2023-06-30 | -0.95 |
| 2023-03-31 | -0.97 |
| 2022-12-31 | -0.95 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
